Company intelligence / Profile preview

Fibronostics

Orlando, Florida, United States

Ownership: Private
Development stage: Other

Overview

LIVERFASt™ has been validated for noninvasive staging of liver fibrosis, steatosis, and activity using AI and biomarker analysis; commercialized on four continents, it is adopted by clinicians as an alternative to invasive biopsies for MASH/MASLD and other liver diseases. The platform is integrated into clinical practice and approved for reimbursement in the US with a CPT code.

Therapeutic areas: NephrologyCardiovascularEndocrinologyInfectious DiseasesGastroenterologyMetabolic Disorders
Modalities: DeviceBiologic (biomarker/fixed panel-based diagnostics)Artificial intelligence diagnostic algorithm
Industry: Metabolite Diagnostics

Partnerships

Stone Diagnostics

Beyond the preview

Go deeper on Fibronostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fibronostics.

Explore the full profile